Investigation for Investors in NASDAW: AVXL shares over potential Securities Laws Violations by Anavex Life Sciences Corp. announced

An investigation on behalf of investors of Anavex Life Sciences Corp. (NASDAQ: AVXL) shares over potential securities laws violations by Anavex Life Sciences Corp. and certain of its directors and officers in connection with certain financial statements was announced.

Investors who purchased shares of Anavex Life Sciences Corp. (NASDAQ: AVXL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Anavex Life Sciences Corp. (NASDAQ: AVXL) concerning whether a series of statements by Anavex Life Sciences Corp. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

New York based Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases.

Before the market opened on February 1, 2022, Anavex Life Sciences Corp. announced that a phase 3 trial of ANAVEX2-73 (blarcamesine) for Rett syndrome met primary and secondary endpoints. Following the announcement, several people on social media indicated that the primary and secondary endpoints were recently changed. STAT’s Adam Feuerstein tweeted, “Anavex changed the primary and secondary endpoints of this Rett study on Jan. 18, allowing it to claim success when the drug most likely failed.”

Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) declined from $19.83 per share in December 2021 to as low as $9.93 per share on February 4, 2022.

Those who purchased shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.